24 results
6-K
EX-99.1
SPRC
SciSparc Ltd
8 Mar 24
SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology
9:00am
Research, the global opioid market was valued at $22.8 billion in 2022 and is anticipated to grow at a compound annual growth rate of 1.4% from 2023 … to 2030. The increasing rate of regulatory approvals and the launch of new opioid medicines to treat patients with chronic pain are the factors expected
F-1
SPRC
SciSparc Ltd
27 Feb 24
Registration statement (foreign)
4:15pm
.
implementation of the federal physician payment transparency requirements, or the Sunshine Act. The Substance Use-Disorder Prevention that Promotes Opioid … . It is a major symptom in many medical conditions and can interfere with a person’s quality of life and general functioning. Opioid medications can provide
6-K
EX-99.1
SPRC
SciSparc Ltd
31 Oct 23
SciSparc Granted Patent from the Australian Patent Office for its Reduction of Opioids Use in Pain Management Technology
8:15am
to a report by Grand View Research entitled “Opioid Market Size, Share & Trends Analysis Report By Product (IR/ Short Acting Opioids, ER/Long-Acting Opioids … ”, the global opioid market size was valued at $22.8 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 1.4% from 2023
6-K
EX-99.1
aii322ztmd0gc or5
1 Jun 22
SciSparc to Collaborate with Polyrizon for Brain Targeting Using Intranasal Hydrogel Systems
4:11pm
6-K
EX-99.1
lcxcb 2d1
2 Dec 20
Therapix Biosciences to Collaborate with The University of Calgary to Further Examine its Proprietary Drug Candidate THX-160 for Pain
9:25am
424B4
q9j8zpo76ej bt4
2 Apr 20
Prospectus supplement with pricing info
5:28pm
F-1/A
5x2spuagotofaa5fu6il
31 Mar 20
Registration statement (foreign) (amended)
11:31am
F-1/A
si0n2k7l39xmf k4u8
30 Mar 20
Registration statement (foreign) (amended)
12:29pm
F-1/A
hjxarzxnphn30ym
26 Mar 20
Registration statement (foreign) (amended)
12:00am
F-1/A
t51xg0 lt
19 Mar 20
Registration statement (foreign) (amended)
12:21pm
424B5
li3dp75cp2vbr tt0p
5 Dec 19
Prospectus supplement for primary offering
5:29pm
424B5
4pemg31oygefbdn
1 Apr 19
Prospectus supplement for primary offering
6:57am
6-K
EX-99.1
ddxt0p mytylfrpq3sq
6 Dec 18
Therapix Biosciences Reports Third
6:18am
424B2
uszjpfb
9 Aug 18
Prospectus for primary offering
11:19am